CHMP fandt derfor, at de gavnlige virkninger opvejer de fundne risici, ligesom det er tilfældet for EPREX/ ERYPO.
Therefore, the CHMP’ s view was that, as for EPREX/ ERYPO, the benefit outweighs the identified risks.